Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 12;14(2):e0212046.
doi: 10.1371/journal.pone.0212046. eCollection 2019.

Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015

Marjan van den Akker  1   2 , Bert Vaes  2 , Geert Goderis  2 , Gijs Van Pottelbergh  2 , Tine De Burghgraeve  2 , Séverine Henrard  2   3
Affiliations

Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015

Marjan van den Akker et al. PLoS One. .

Abstract

Objectives: The aim of this paper was to describe the time trends in the prevalence of multimorbidity and polypharmacy in Flanders (Belgium) between 2000 and 2015, while controlling for age and sex.

Methods: Data were available from Intego, a Flemish-Belgian general practice-based morbidity registration network. The practice population between 2000 and 2015 was used as the denominator, representing a mean of 159,946 people per year. Age and gender-standardised prevalence rates were used for the trends of multimorbidity and polypharmacy in the total population and for subgroups. Joinpoint regression analyses were used to analyse the time trends and breaks in trends, for the entire population as well as for specific age and sex groups.

Results: Overall, in 2015, 22.7% of the population had multimorbidity, while the overall prevalence of polypharmacy was 20%. Throughout the study period the standardised prevalence rate of multimorbidity rose for both sexes and in all age groups. The largest relative increase in multimorbidity was observed in the younger age groups (up to the age of 50 years). The prevalence of polypharmacy showed a significant increase between 2000 and 2015 for all age groups except the youngest (0-25 years).

Conclusion: For all adult age groups multimorbidity and polypharmacy are frequent, dynamic over time and increasing. This asks for both epidemiological and interventional studies to improve the management of the resulting complex care.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Age trends in the proportions of multimorbidity for males and females (point prevalence, 95% CI).
Fig 2
Fig 2. Evolution of the age- and sex-standardised prevalence rate of multimorbidity from 2000–2015.
Fig 3
Fig 3. Evolution of the age- and sex-standardised and crude prevalence rates of polypharmacy (≥5 drugs) from 2000–2015.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name? A review of literature. Eur J Gen Pract. 1996;2:65–70.
    1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230 Epub 2017/10/12. 10.1186/s12877-017-0621-2 . - DOI - PMC - PubMed
    1. Sinnott C, Bradley CP. Multimorbidity or polypharmacy: two sides of the same coin? Journal of Comorbidity. 2015;5(29–31). 10.15256/joc.2015.5.51 - DOI - PMC - PubMed
    1. Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: An overview of systematic reviews. Ageing Res Rev. 2017;37:53–68. Epub 2017/05/18. 10.1016/j.arr.2017.05.003 . - DOI - PubMed
    1. McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk management and healthcare policy. 2016;9:143–56. Epub 2016/07/28. 10.2147/RMHP.S97248 . - DOI - PMC - PubMed